Introduction
Mangiferin (seen in Fig. 1 ), a natural bioactive xanthone C-glycoside originated from Mangifera indica L. (Anacardiaceea) (Aritomi and Kawasaki, 1969) , possesses a wide spectrum of pharmacological activities, including antioxidant (Das et al., 2012) , anti-inflammatory (Das et al., 2012) , antidiabetic (Sellamuthu et al., 2009) , anticancer (Shoji et al., 2011) , antibacterial (Savikin et al., 2009) , anti-HIV , and radioprotective (Jagetia et al., 2005) actions.
Owing to its remarkable bioactivities, mangiferin has attracted increasing attention as a potential candidate.
Increasing evidence suggests that mangiferin exerts antidiabetic activity in genetic diabetes rats such as KK/Ay mice (Ichiki et al., 1998) and Zucker diabetic fatty (ZDF) rats (functions as a PPAR-γ activator) (Huang et al., 2006) , as well as STZ-induced diabetic rats (Muruganandan et al., 2005) . The expression levels of several hepatic and intestinal cytochrome P450 (CYP 450) isozymes, such as CYP1A1, 1A2, 1B1, 2B1, 3A1, 3A2, 3A4, 4A1, 4A2, and 2E1 (Raza et al., 1996; Engels et al., 1999; Sindhu et al., 2006; Borbás et al., 2006) , as well as sulfotransferases (SULT), uridine diphosphate glucuronosyltransferases (UGT), and catechol O-methyltransferase (COMT) (Runge-Morris and Vento, 1995; Tunon et al., 1999; Wang et al., 2002) involved in phase Ⅱ metabolism are altered in STZ-induced diabetic rats. Furthermore, an increase in hepatic blood flow rate (Sato et al., 1991) , a higher incidence of hepatic impairment (Watkins and Sherman, 1992) , and kidney function impairment (Nadai et al., 1990) were also reported in diabetic rats.
Research work by Yu et al. (2010) provided experimental evidence that impaired function and expression of P-glycoprotein (P-gp) in the small intestines were important events in a diabetic rat model induced by STZ, resulting in an increased absorption of P-gp substrates. As a P-gp substrate This article has not been copyedited and formatted. The final version may differ from this version. (Chieli et al., 2010) , mangiferin was subjected to extensive phase Ⅰ and phase Ⅱ metabolism in vivo after oral administration (Liu et al., 2011) . All these results demonstrated that diabetes mellitus may alter the pharmacokinetic and metabolic behaviors of mangiferin. Nevertheless, investigations of metabolism and pharmacokinetics of mangiferin were mainly focused on conventional rats up to now and there is no published literature on the pharmacokinetics and metabolism of mangiferin in animals under diabetic conditions. Considering the antidiabetic effects of mangiferin, it is important to investigate its pharmacokinetics and metabolism in diabetic animals.
Previous in vitro studies (Sanugul et al., 2005; Liu et al., 2011; Braune and Blaut, 2011) indicated that mangiferin might be metabolized into norathyriol by the intestinal flora. Thus, it is conceivable that the role of intestinal flora in the metabolism of mangiferin is critical and its alternations may affect the metabolic and pharmacokinetic behavior of mangiferin in vivo. To the best of our knowledge, however, no published paper provided unequivocal evidence on the role of the intestinal flora in the in vivo disposition of mangiferin.
Therefore, a systematic and comparative investigation of the metabolism and pharmacokinetics of mangiferin in conventional rats, pseudo-germ-free rats, and STZ-induced diabetic rats was conducted in the present study. In addition, P-gp and main metabolic enzymes expressions at the mRNA level were also investigated using a real-time quantitative RT-PCR assay.
This article has not been copyedited and formatted. The final version may differ from this version. and daidzin (internal standard, IS) were purchased from the National Institute for Control of Pharmaceutical and Biological Products (Beijing, China). Streptozotocin, streptomycin, and neomycin sulfate were purchased from Sigma Chemical Co. (St Louis, MO, USA). Norathyriol and 1, 7-dihydroxyxanthone (99% pure) were isolated and identified by our laboratory from the rat urine after oral administration of mangiferin (Wang et al., 2007) . The high-performance liquid chromatography (HPLC)-grade acetonitrile and formic acid were from Fisher Chemical Co., Inc.
(CA, USA). The UNIQ-10 column mRNA purification kit and primers were from Sangon Biotech The diabetic rats were induced by intraperitoneal administration of 65 mg/kg STZ (dissolved in sodium citrate buffer, pH 4.5). The weight, fasting blood glucose, and plasma insulin levels of the rats were measured at 3, 7, 10, and 14 days following injection of STZ. The STZ-induced hyperglycemic state in the rats was considered an animal model of type I diabetes mellitus (Kamei et al., 2005) .
For metabolism and pharmacokinetic study, the rats were divided into three drug-treated groups (ten conventional rats in group A, ten pseudo-germ-free rats in group B, and twenty STZ-induced diabetic rats in group C, respectively; with five rats per group for urine and feces collecting and the rest for blood withdrawn) and one control group consisting of six rats. The rats were fasted overnight with free access to water prior to administration of a single oral dose (400 mg/kg) of mangiferin. For gene expression investigation, another fifteen rats were divided into three groups (five conventional rats in group A, five pseudo-germ-free rats in group B and five STZ-induced diabetic rats in group C). Small intestines were collected from all three groups while livers were collected from groups A and C. All animal studies were in accordance with the guidelines of the Metabolism study. The urine and feces of rats during the period of 0-48 h post-dose were collected and combined separately. Pretreatment of the urine and feces samples was according to the method described in previous literature (Liu et al., 2011) . The residues were dissolved in 100 μ L of 80 % methanol and centrifuged twice at 15,000 × g for 10 min prior to analysis. Plasma samples at each time point were combined for metabolic study after pharmacokinetic analysis. All the blank samples as control were prepared with the same method as drug containing samples. 
Results
Method validation for pharmacokinetic study. A full validation of the HPLC-DAD method was performed with regard to selectivity, lower limit of quantification (LLOQ), linearity, accuracy, precision, recovery, and stability. Typical chromatograms (as shown in Fig. 2 ) demonstrated that neither endogenous interference nor metabolites were observed at the retention time of the analyte and IS in the chromatograms of the drug-free plasma from six different rats. The retention times of mangiferin and daidzin were 5.5 and 9.5 min, respectively.
The standard calibration curve for mangiferin, which was constructed for five consecutive days by plotting the peak area ratios of mangiferin to IS versus the concentration in duplicate, exhibited good linearity over the range of 80 ng/mL to 2500 ng/mL. The regression equation was y=0.0018x+0.0320 (r = 0.9999). The LLOQ was 80 ng/mL.
The precision and accuracy of the method were assessed by replicate analysis of QC samples on the same day (intra-day) (n = 5) and on five consecutive days (inter-day). The method gave good precision and accuracy with the relative standard deviations (RSD) below 7.8 % and accuracy of 97.6% to 102.7% for both intra-day and inter-day QC samples.
The extraction recoveries of mangiferin and IS were determined at three QC levels by comparing the peak areas obtained after extraction with those obtained from direct injections of standard solutions (n=5). The extraction recoveries for mangiferin were 78.4 ± 3.6%, 75.5 ± 4.3%, and 75.8 ± 1.7% at the three concentrations, respectively. The recovery for IS was 85.1 ± 3.2%.
The results of the stability study by QC samples (n=3) analysis indicated that mangiferin was stable in plasma samples for 24 h at room temperature after preparation, within three freeze-thaw cycles, and after storage at -80 °C for 20 days. The deviations from the nominal concentration This article has not been copyedited and formatted. The final version may differ from this version. were within ± 15 %.
Method application to pharmacokinetic study. The validated HPLC-DAD method was successfully applied to pharmacokinetic study of mangiferin in rat plasma. The concentration-time profiles of mangiferin in rat plasma following its oral administration are illustrated in Fig. 3 . The selected pharmacokinetic parameters are listed in Table 2 .
Mangiferin was absorbed rapidly in conventional rats, and its high concentration level could only be detected at 0.73 ± 0.72 h after oral administration. This phenomenon was consistent with the research results by Liu et al. (2010) . Published literature by Han (Han et al., 2010) has reported that mangiferin was poorly absorbed and its bioavailability was only 1.2%. In the present study, the plasma maximum concentration (C max ) and area under concentration-time curve (AUC 0-24 ) of mangiferin after oral administration to conventional rats were 715.04 ± 600.14 ng/mL and 3799.68 ± 1833.24 ng h/mL, respectively. Statistically significant differences were observed between conventional rats and STZ-induced diabetic rats with respect to pharmacokinetic parameters including C max , AUC 0-t , AUC 0-∞ , mean residence time (MRT 0-t , MRT 0-∞ ), and oral clearance (CL/F). Compared with conventional rats, the diabetes conditions induced 2.79-and 2.35-fold increase of C max and AUC 0-t for mangiferin, respectively. MRT 0-t and CL/F values of mangiferin in conventional rats were 1.42-and 2.62-fold increased, respectively, compared with corresponding parameters observed in STZ-induecd diabetic rats. However, no significant differences were observed with regard to the time to reach C max (T max ) and elimination half-life (T 1/2 ) between conventional rats and diabetic rats. As intestinal flora was inhibited in pseudo-germ-free rats, no significant differences were observed between conventional rats and pseudo-germ-free rats with respect to all pharmacokinetic parameters as presented in Table 2 .
This article has not been copyedited and formatted. The final version may differ from this version. Characterization of mangiferin and its metabolites. On the basis of the direct comparison of samples from drug-treated and corresponding control animals, a total of forty-eight metabolites were detected and their structures were elucidated based on the characteristics of their parent ions, product ions, and chromatographic behavior. Extracted ion chromatograms (EIC) of mangiferin and its metabolites are presented in Fig. 4 . Detection, identification, MS n and retention data of mangiferin and its metabolites are summarized in Table 3 .
Identification of metabolites via direct comparison with the standards and published literature (M0-M12, M14, M17-M26, M28-M29, M32-M36, M38, and M40-M47). The metabolites were
characterized by comparing the characteristics of their precursor ions, product ions and chromatographic retention times with those of the standards and compounds described in the literature (Lai et al., 2003; Liu et al., 2011) . Thus, M0, M32, and M47 were unambiguously identified as mangiferin, norathyriol, and 1, 7-dihydroxanthone, respectively, whereas structures of further thirty-six metabolites (M1-M12, M14, M17-M26, M28-M29, M33-M36, M38, and M40-M46) were tentatively characterized. M13, M15, M16, M27, M30, M31, M37, M39 and M48) . After oral administration of mangiferin to pseudo-germ-free rats, the parent compound appeared in the plasma, urine and feces. Moreover, six metabolites (M3, M4, M6, M12, M14, and M21) in the urine, and one metabolite (M14) in the feces were also detected.
Structure elucidation of other metabolites (
mRNA expression of P-gp in rat intestine. The results presented in Fig. 5 indicated that mdr1a levels in the duodenum, jejunum, and ileum of the pseudo-germ-free rats increased, whereas mdr1b levels decreased in these sections, as compared with conventional rats. The mdr1a level in the ileum increased while its level in the duodenum and the mdr1b mRNA levels in the duodenum, jejunum, and ileum decreased in diabetic rats as compared with conventional rats. UGT1A8, UGT2B8, and SULT1A1 mRNA levels, whereas COMT, UGT2B6, UGT2B12 and SULT1C1 mRNA levels were down-regulated.
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Discussion
Pharmacokinetic studies of mangiferin in conventional rats, STZ-induced diabetic rats, and pseudo-germ-free rats were conducted. A two-tailed t-test was applied to the obtained pharmacokinetic parameters. P-values of six pharmacokinetic parameters, including C max , AUC 0-t , AUC 0-∞ , MRT 0-t , MRT 0-∞ , and CL/F obtained from STZ-induced diabetic rats versus the conventional rats were all lower than 0.01, indicating that the pharmacokinetic profiles of mangiferin in conventional rats and diabetic rats were statistically different. An increased exposure of mangiferin was found in the plasma of STZ-induced diabetic rats with C max and AUC 0-t values being 2.79-and 2.35-fold increased, respectively, compared with that in conventional rats.
Nevertheless, p-values of the pharmacokinetic parameters obtained from pseudo-germ-free rats versus the conventional rats were all higher than 0.05, and no significant statistical differences in pharmacokinetic behaviors were observed.
P-glycoprotein (permeability-glycoprotein, abbreviated as P-gp or Pgp), one of the efflux pumps, plays an important role not only in xenobiotic detoxification and the bio-defense system, but also in drug pharmacokinetics and pharmacodynamics. This protein, known as multidrug resistance protein 1 (MDR1), exists as two-functional glycoprotein isoforms that are encoded by two different genes: mdr1a and mdr1b. As a substrate of P-gp, the systematic exposure of mangiferin might be to a large extent dependent on the expression of P-gp in the intestines of rats.
Thus, alterations of intestinal P-gp will very likely influence the pharmacokinetics of mangiferin.
Previous studies by Yu et al. (2010) indicated impaired function and decreased expression of P-gp in the small intestine of diabetic rats. In the present study, a real-time quantitative RT-PCR assay was also conducted to compare the mdr1 mRNA levels in the small intestines of conventional rats, This article has not been copyedited and formatted. The final version may differ from this version. STZ-induced diabetic rats, and pseudo-germ-free rats. The mdr1a mRNA level in the duodenum, and mdr1b mRNA levels in the duodenum, jejunum, and ileum of STZ-induced diabetic rats were 2.27-, 2.06-, 1.89-, and 3.14-fold decreased, respectively, compared with that in conventional rats.
The mdr1b mRNA level in the ileum of STZ-induced diabetic rats was 2.31-fold increased compared with that in conventional rats, whereas no significant changes of the mdr1b mRNA level in the jejunum were observed. Thus, the mdr1 mRNA levels in the duodenum and jejunum of STZ-induced diabetic rats were down-regulated compared with conventional rats, whereas opposing changes were observed in the mdr1a and mdr1b mRNA level of the ileum. The mdr1a mRNA levels in the duodenum, jejunum, and ileum of pseudo-germ-free rats were 2.69-, 1.70-, and 3.45-fold increased, respectively, compared with that in conventional rats. On the contrary, the mdr1b mRNA levels in the duodenum, jejunum, and ileum of pseudo-germ-free rats were 1.88-, 2.31-, and 4.89-fold decreased, respectively, compared with that in conventional rats. The results indicated that the mdr1 mRNA levels were also affected by antibiotics, and opposing changes were observed in the mdr1a and mdr1b mRNA levels. The changes of the mdr1a and mdr1b mRNA levels in the small intestines of STZ-induced diabetic rats and pseudo-germ-free rats might partially explain the different pharmacokinetic behaviors of mangiferin among conventional rats and model rats.
In our previous research (Liu et al., 2011) , a total of thirty-three metabolites in the urine, plasma, and feces of the conventional SD rats were detected after oral administration of mangiferin at a single dose of 200 mg/kg body weight. Nevertheless, in the present study, only twenty-two metabolites of mangiferin were screened after oral administration of mangiferin at a dose of 400 mg/kg body weight to conventional Wistar rats. We concluded that this phenomenon might be This article has not been copyedited and formatted. The final version may differ from this version. conjugates. On the other hand, mangiferin was initially deglycosylated to be transformed into norathyriol, which further was subjected to methylation, reglycosylation, dehydroxylation, glucuronidation, and sulfation.
Although mangiferin in STZ-induced diabetic rats was subjected to similar metabolic pathways with that in conventional rats after its oral administration, the number of metabolites detected in the plasma and urine samples of STZ-induced diabetic rats was greater than that in conventional rats. Hepatic and kidney functions, as well as the enzymes involved in phase Ⅰ and phase Ⅱ metabolism, underwent apparent changes in animals under diabetic status (Nadai et al., 1990; Sato et al., 1991; Watkins and Sherman, 1992; Runge-Morris and Vento, 1995; Raza et al., 1996; Engels et al., 1999; Tunon et al., 1999; Sindhu et al., 2006; Wang et al., 2002; Borbás et al., 2006) .
Thus, it is no surprising that the metabolic behavior of mangiferin after its oral administration was subjected to great changes in rats under diabetic status compared with conventional rats. To further elucidate the different metabolic behaviors especially differences in the phase UGT2B8, and UGT2B12), and sulfation (SULT1A1, SULT1C1) underwent significant changes under diabetic conditions. The mRNA levels of UGT1A3, UGT1A8, UGT2B8, and SULT1A1 in the liver of STZ-induced diabetic rats were 2.28-, 3.93-, 4.39-, and 1.62-fold increased, respectively, compared with that in conventional rats. Nevertheless, the mRNA levels of COMT, UGT2B6, UGT2B12, and SULT1C1 in the liver of STZ-induced diabetic rats were 1.72-, 2.13-, 2.00-, and 6.67-fold decreased, respectively, compared with that in conventional rats. Thus, the diabetic status induced up-regulations of UGT1A3, UGT1A8, UGT2B8, and SULT1A1 mRNA levels and down-regulations of COMT, UGT2B6, UGT2B12, and SULT1C1 mRNA levels, which could partially explain the differences of metabolic behaviors between conventional rats and STZ-induced diabetic rats.
Our previous research (Liu et al., 2011) indicated that mangiferin could be transformed into norathyriol by the intestinal flora in vitro. In addition, Sanugul et al. (2005) and Braune et al.
(2011) have isolated human intestinal bacterium, named B. sp. MANG and CG19-1, respectively, both of which could transform mangiferin into its aglycone-norathyriol in vitro. In the present study, a much more reliable and creditable in vivo method was used to clarify the role of intestinal flora played in the metabolism and pharmacokinetics of mangiferin. As the intestinal flora was inhibited with antibiotics, only monomethylated, monomethylated and monoglucuronidated, and monomethylated and monosulfated metabolites of mangiferin were detected after oral administration, whereas the aglycone of mangiferin and its sequential phase pseudo-germ-free rats, and STZ-induced diabetic rats after its oral administration are proposed and summarized in Fig. (7-9) .
This article has not been copyedited and formatted. The final version may differ from this version. h after oral administration of mangiferin to pseudo-germ-free rats, (E) plasma sample 4 h after oral administration of mangiferin to STZ-induced diabetic rats. 
